2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 6.158

Change

-0.04 (-0.61)%

Market Cap

USD 0.52B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.07% 48% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.07% 44% F 50% F
Trailing 12 Months  
Capital Gain 14.21% 51% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.21% 47% F 51% F
Trailing 5 Years  
Capital Gain 56.49% 72% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.49% 72% C 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.38% N/A N/A 59% D-
Dividend Return 5.38% N/A N/A 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.57% N/A N/A 80% B-
Risk Adjusted Return 39.61% N/A N/A 62% D
Market Capitalization 0.52B 60% D- 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike